Search Results - "Ercelep, O."

The prevalence of gastroesophageal reflux disease among hospital employees by Ercelep, O. B., Caglar, E., Dobrucali, A.

“…Summary Quantitative estimate of the actual prevalence of the gastroesophageal reflux disease (GERD) is difficult to obtain because most of the patients with…”
Get full text

Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer by Ercelep, O., Alan, O., Sahin, D., Telli, T. A., Salva, H., Tuylu, T. B., Babacan, N. A., Kaya, S., Dane, F., Ones, T., Alkis, H., Adli, M., Yumuk, F.

“…Purpose The standard treatment for patients with stage III non-small cell lung cancer (NSCLC), unsuitable for resection and with good performance, is…”
Get full text

Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy by Aydin, D., Bilici, A., Yavuzer, D., Kefeli, U., Tan, A., Ercelep, O., Mert, A., Yuksel, S., Ozcelik, M., Isik, D., Surmeli, H., Odabasi, H., Aliustaoglu, M.

“…Backgrounds A disintegrin and metalloproteinase (ADAM) 17 has been indicated to be an indispensable regulator of cellular events from proliferation to…”
Get full text

The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients by Ozcelik, M., Odabas, H., Ercelep, O., Yuksel, S., Mert, A. G., Aydin, D., Surmeli, H., Isik, D., Isik, S., Oyman, A., Oven Ustaalioglu, B. B., Aliustaoglu, M., Gumus, M.

“…Aim The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is complicated by a lack of general agreement. The aim of this study was to…”
Get full text

1464P - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer by Işıkdoğan, A., Akdeniz, N., Küçüköner, M., Kaplan, M.A., Urakçı, Z., Karhan, O., Sezgin, Y., Bilen, E., Ebinç, S., Teke, F., Laçin, Ş, Alan, O., Ercelep, O., Yumuk, F.

“…The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide…”
Get full text

Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer by Işıkdoğan, A., Akdeniz, N., Küçüköner, M., Kaplan, M.A., Urakçı, Z., Karhan, O., Sezgin, Y., Bilen, E., Ebinç, S., Teke, F., Laçin, Ş, Alan, O., Ercelep, O., Yumuk, F.

Get full text

1464PComparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer by Işıkdoğan, A, Akdeniz, N, Küçüköner, M, Kaplan, M A, Urakçı, Z, Karhan, O, Sezgin, Y, Bilen, E, Ebinç, S, Teke, F, Laçin, Ş, Alan, O, Ercelep, O, Yumuk, F

“…Abstract Background The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear…”
Get full text

The prevalence of gastroesophageal reflux disease among hospital employees: Prevalence of reflux disease by Ercelep, O. B., Caglar, E., Dobrucali, A.

Get full text

Three Different Chemotherapy Combinations with Concurrent Thoracic Radiation for Patients with Stage III Non-Small Cell Lung Cancer by Ozcelik, M., Ercelep, O. Balvan, Mert, A. Guven, Yuksel, S., Ozdemir, P., Surmeli, H., Isık, D., Aydin, D., Korkmaz, T., Odabas, H., Aliustaoglu, M., Gemici, C., Mayadagli, A., Gumus, M.

Get full text

1204PTHREE DIFFERENT CHEMOTHERAPY COMBINATIONS WITH CONCURRENT THORACIC RADIATION FOR PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER by Ozcelik, M., Ercelep, O. Balvan, Mert, A. Guven, Yuksel, S., Ozdemir, P., Surmeli, H., Isık, D., Aydin, D., Korkmaz, T., Odabas, H., Aliustaoglu, M., Gemici, C., Mayadagli, A., Gumus, M.

“…Abstract Aim: Stage III non-small cell lung cancer (NSCLC) is one of the most controversial areas in managing lung cancer and gives a chance to clinicians to…”
Get full text

Modified Glasgow prognostic score, prognostic nutritional index and ECOG score could be new prognostic factors for survival in metastatic gastric cancer by Demirelli, B., Babacan, N., Koca, S., Uzun, B.N., Ercelep, Ö., Ozturk, M.A., Kaya, S., Simsek, E.T., Khalil, S., Hasanov, R., Alan, O., Telli, T.A., Arıbal, M.E., Dane, F., Yumuk, F.

Get full text